New Comprehensive Report on Bench-top Veterinary Biochemistry Analyzers Market to Witness an Outstanding Growth during 2020 2028 with Top Players…

Overview Of Bench-top Veterinary Biochemistry Analyzers Industry 2020-2028:

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The Bench-top Veterinary Biochemistry Analyzers Market analysis summary by Reports Insights is a thorough study of the current trends leading to this vertical trend in various regions. Research summarizes important details related to market share, market size, applications, statistics and sales. In addition, this study emphasizes thorough competition analysis on market prospects, especially growth strategies that market experts claim.

Bench-top Veterinary Biochemistry Analyzers Market competition by top manufacturers as follow: Idexx Laboratories, Abaxis, Heska, Fuji Film, DiaSys Diagnostic Systems, Randox Laboratories, LITEON, URIT Medical Electronic, Scil Animal Care, BPC BioSed, AMS Alliance, Carolina Liquid Chemistries, Crony Instruments, iCubio

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/132415

The global Bench-top Veterinary Biochemistry Analyzers market has been segmented on the basis of technology, product type, application, distribution channel, end-user, and industry vertical, along with the geography, delivering valuable insights.

The Type Coverage in the Market are:

AutomaticSemi-automatic

Market Segment by Applications, covers:

Veterinary HospitalsVeterinary Clinics

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Major factors covered in the report:

To get this report at a profitable rate.: https://reportsinsights.com/discount/132415

The analysis objectives of the report are:

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Bench-top-Veterinary-Biochemistry-Analyzers-Market-132415

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

More here:
New Comprehensive Report on Bench-top Veterinary Biochemistry Analyzers Market to Witness an Outstanding Growth during 2020 2028 with Top Players...

Impact Of Outbreak Of Covid-19 Pandemic On Automatic Veterinary Biochemistry Analyzer Market 2020 Growth Factors | Strategic Analysis | Increasing…

Global Automatic Veterinary Biochemistry Analyzer Market 2020: Business Growth Rate, Manufacturing Analysis, Size, Share, Cost Structure, and Forecast to 2026

The Market Data Analytics published a recent report on the globalAutomatic Veterinary Biochemistry Analyzer market, which was studied by the research analysts for months. The report includes information from trusted primary and secondary resources along with detailed examination from the research analysts. Based on the analysis, research analysts have concluded that the global demand for the global Automatic Veterinary Biochemistry Analyzer market was USD XX Million in 2019 and is anticipated to reach USD XX Million by the end of 2026. The expected CAGR for the market is around XX%.

Ask for a Sample Copy of the Report (Use Corporate email ID to Get Higher Priority):https://www.marketdataanalytics.biz/global-automatic-veterinary-biochemistry-analyzer-market-industry-trends-and-22525.html#request-sample

Final Report will add the analysis of the impact of COVID-19 on this Industry.

The other factors that the report delivers is the revenue estimations, sales volume, industry size, and other important aspects, which includes market segmentation, growth factors, restraints, opportunities, challenges, and the market players.

The global Automatic Veterinary Biochemistry Analyzer market incorporates information such as the basic overview of the industry, which includes definition, segmentation, and the industry structure. The global Automatic Veterinary Biochemistry Analyzer market is segmented on the basis of{Bench-Top Veterinary Biochemistry Analyzer, Portable Veterinary Biochemistry Analyzer}; {Pet Hospital, Veterinary Station}. Along with this the product types and the applications of the Automatic Veterinary Biochemistry Analyzer market are also discussed. Other data that is provided includes developmental trends, regional analysis of the Automatic Veterinary Biochemistry Analyzer market, and the technological advancements. The developmental policies that have been updated are all discussed in the report.

Browse Full Report with More Professional and Technical Insights Including COVID-19 Impact@https://www.marketdataanalytics.biz/global-automatic-veterinary-biochemistry-analyzer-market-industry-trends-and-22525.html

Some of the top most key players that are enlisted in the report areBiochemical Systems International, BPC BioSed, Carolina Liquid Chemistries, Abaxis Europe, AMS Alliance, Randox Laboratories, Rayto Life and Analytical Sciences, Scil Animal Care, Crony Instruments, DiaSys Diagnostic Systems, Eurolyser Diagnostica, Gesan Production, Heska, Idexx Laboratories, LITEON IT Corporation, Shenzhen Icubio Biomedical Technology, URIT Medical Electronic. The details that are represented in the report includes the cost structures, manufacturing process methodology, import and export consumption, supply and demand patterns, gross margins, recent developments made in the business, revenue analysis, and gross margins.

The report offers a comprehensive understanding of market dynamics across key regions, namely North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), Latin America (Brazil, Argentina), and the Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa).

Contact Us For More Inquiry of Automatic Veterinary Biochemistry Analyzer Report at::https://www.marketdataanalytics.biz/global-automatic-veterinary-biochemistry-analyzer-market-industry-trends-and-22525.html#inquiry-for-buying

Key Questions Answered In The Report:

What is the growth potential of the global Automatic Veterinary Biochemistry Analyzer market? Which regional market will emerge as a frontrunner during the forecast period 2020-2026? Which application segment will grow at a robust rate? What are the growth opportunities that may emerge in the industry in the years to come? What are the key challenges that the global market may face in the future? Which are the main companies in the global Automatic Veterinary Biochemistry Analyzer market? Which are the growth strategies considered by the players to sustain hold in the global market?

Why Go For Market Data Analytics Research?

Market Data Analytics is a leading global market research and consulting firm. We focus on business consulting, industrial chain research, and consumer research to help customers provide non-linear revenue models. We believe that quality is the soul of the business and that is why we always strive for high quality products. Over the years, with our efforts and support from customers, we have collected inventive design methods in various high-quality market research and research teams with extensive experience.

Read more:
Impact Of Outbreak Of Covid-19 Pandemic On Automatic Veterinary Biochemistry Analyzer Market 2020 Growth Factors | Strategic Analysis | Increasing...

Honey Bee Nutrition Might Be Key To Healthy Colonies – Texas A&M Today – Texas A&M University Today

To prevent future managed colony losses, the team will look for ways to strengthen bee colony immunity by feeding them more nutritious diets.

Getty Images

A newly fundedTexas A&M AgriLife Researchproject seeks to slow population losses among more than 2.6 million managed honey bee colonies in the U.S.

Honey bees provide pollination services that uphold $16 billion in U.S. agricultural crops. However, managed colonies have seen annual declines. Those include a 40% decline as recently as 2018-2019, said Juliana Rangel, AgriLife Research honey bee scientist in the Department of Entomology, Bryan-College Station.

The declines are attributed to several general issues, including poor nutrition and susceptibility to pathogens and diseases, said Pierre Lau, AgriLife Research graduate assistant and a Texas A&M Universitydoctoral candidate in Rangels laboratory.

Lau is also the project leader. To prevent future managed colony losses, his team will look for ways to strengthen bee colony immunity to disease pathogens by feeding them more nutritious diets.

The project is supported by aU.S. Department of Agriculture pre-doctoral fellowshiptitled Optimizing Macronutrient Contents in the Honeybee Diet as a Mechanism for Pathogen Defense.

The research team includes Lau, Texas A&M graduate student Alexandria Payne, undergraduate students Cora Garcia and Jordan Gomez, and Rangel. Spencer Behmer, AgriLife Research professor in the Texas A&M department of entomology, is also part of the team, as is his postdoctoral research associate Pierre Lesne.

Cups with different macronutrient mixes are presented to bees in these small cups.

Texas A&M AgriLif

Researchers will focus heavily on macronutrients, which are those nutrients in the highest demand by a healthy body for proper metabolism and physiology, Lau said.

His teams work will be to first understand the varying amounts of proteins and lipids, or macronutrient ratios, present in bees diets. They will work to optimize an ideal diet with varying ratios of macronutrients, then they will observe physiological benefits to bees that receive increasingly nutritious dietary mixes.

Commercial honey bee colonies succumb especially to Nosema ceranae and deformed wing virus. Nosema ceranae, a fungal pathogen, causes a fatal intestinal disease, while deformed wing virus causes death due to developmental complications in heavily infected adults, particularly due to crumpled wings.

Besides pathogens and diseases, Lau said, honey bee declines within agroecosystems which describe most agricultural crop scenarios can also come from parasitization, poor queen health, pesticide exposure and landscape fragmentation.

As such, in addition to immunity, the researchers will investigate how nutritional changes affect expression of genes that mediate proper honey bee development and growth.

We know that pollen is the most important source of nourishment for bees, but as a field of research, we have a poor understanding of all the macronutrients that make up pollen, Lau said.

At the same time, Lau and collaborators, in an unpublished study, were able to determine the nutritional content of certain pollens. In the same study, they noted that honey bees preferred pollen with a lower ratio of protein to lipids, or P:L ratio, than what would be currently available in the beekeeping industry. Moreover, Lau said, existing research shows that organisms naturally seek out pathogen-fighting nutrients in their surroundings.

Does this mean that honey bees can alter their macronutrient intake to self-medicate and increase their tolerance to a pathogen, given the availability? Lau said. It could also be that the role of lipids is more significant than we understand.

Additionally, Rangel said, honey bees need certain plants in the vicinity to help them with physiological processes. Those include metabolizing certain macro and micronutrients.

We know that honey bees need variety in their diet, Rangel said. But, to what extent are certain nutrients required, or even sought after, by the bees for proper nourishment?

Can we introduce supplemental macronutrients that allow honey bees to self-medicate in the presence of pathogen infections? Lau added. This will be our focus for the next two years.

Read more about theTexas A&M Honey Bee Research Program , and follow Rangels lab onFacebook.

Read the original post:
Honey Bee Nutrition Might Be Key To Healthy Colonies - Texas A&M Today - Texas A&M University Today

HRI sheds further light on relationship between diet and cardiometabolic disease – Mirage News

Recent HRI research has validated the metabolic pathways that link dietary components with the risk of developing cardiovascular disease.

A study led by the Heart Research Institutes Dr Yen Chin Koay in collaboration with research colleagues Dr Jibran Wali and Professor Stephen Simpson from Charles Perkins Centre, The University of Sydney focuses on dimethylguanidino valeric acid (DMGV), a marker of fatty liver disease, incident coronary artery disease, cardiovascular mortality, and incident diabetes.

The research, published in The American Journal of Physiology, investigates the relationship between dietary macronutrients and circulating levels of DMGV and other related metabolites with insulin resistance.

Our research provides insight into recent observations of dietary control of this promising new marker of cardiometabolic disease and novel disease pathway, says Dr Koay, postdoctoral researcher in HRIs Cardiometabolic Disease Group led by Assoc Prof John OSullivan.

Identifying the modifiable metabolic pathways linking the dietary components of cardiometabolic disease could help to reduce disease risk and lead to new avenues for prevention.

The research measured the plasma concentrations of DMGV and its related metabolites and analysed the dietary data to validate the dietary associations in various cohorts. The results found that DMGV concentrations were significantly upregulated in people with liver or skeletal muscle insulin resistance and that DMGV levels were upregulated in lab models on a very high sucrose diet.

These results provide a comprehensive picture of the dietary determinants of DMGV levels and its association with insulin resistance, says Dr Koay.

The study also extends the clinical value of DMGV as a predictor of exercise responsiveness to global metabolic health, including ectopic lipid deposition and insulin resistance in muscle and liver.

In the next phase of research, the teams goal is to understand the mechanisms that link plasma levels of DMGV, lifestyle, and dietary interventions.

With this knowledge, we could facilitate development of strategies personalised to the individual to help prevent prediabetes in those at increased risk, states Dr Koay.

This research received an APSselect award for distinction in scholarship by The American Physiological Society.

Continued here:
HRI sheds further light on relationship between diet and cardiometabolic disease - Mirage News

6 things to know about how wildfire smoke impacts your health – KCRA Sacramento

As Northern California sits under a thick blanket of wildfire smoke for days, many people are left wondering what the air quality means for their health.It is really bad, said Dr. Vanessa Walker. As a pulmonary physician with Sutter Health and Pulmonary Medicine Associates, Walker has treated COVID-19 patients throughout the pandemic. Recently, she has seen an uptick in smoke-related hospital visits. To provide context, she said an AQI greater than 100 is unhealthy for sensitive groups. Right now, the AQI is well over 200. So this is unhealthy for everybody no matter who you are. And unfortunately, it just seems to be getting worse especially as these wildfires are raging out of control, she said. Here are six things to know about how smoke impacts your health according to Dr. Walker:1. What are the negative impacts?Walker: If you have no lung disease, youre probably just going to notice things like eye irritation, throat irritation, scratchy nose, watery eyes. But if you have any kind of underlying lung disease, COPD, emphysema, asthma, you can cause a serious reaction like an asthma exacerbation or a COPD exacerbation where you have tightening of your airways, significant coughing, shortness of breath and sometimes even life-threatening airway edema.2. Who are the most vulnerable people?Walker: The most vulnerable groups are going to be young children, pregnant people as well as people with any kind chronic lung condition or heart condition, and the elderly, mostly because people that are older tend to have those underlying conditions. 3. Is it OK to workout outside (even for just a short amount of time)?Walker: That is dangerous. You dont know if youre going to be somebody whos out there for 20 minutes and ends up having an asthma exacerbation or a sudden airway problem.4. What could wildfire smoke mean for contracting COVID-19?Walker: COVID is setting up an inflammatory bomb in your body. And having underlying inflammation from being exposed to wildfire smoke could actually make it harder for your body to fight because of all the inflammation thats already there. This is all conjecture because we dont know. This is all early in COVID. This is all new to us. But just understanding basic physiology, it makes perfect sense that if youre already having inflammation, that COVID could come and significantly make it worse.5. Which masks should you wear to prevent COVID versus wildfire smoke?For COVID only: Cloth or surgical masksWalker: If youre going to be indoors, youre going to be around people, youre going to be going to the grocery store, I think wearing a cloth mask is perfectly fine or a regular surgical mask. Completely adequate.For COVID & wildfire smoke: K95 & N95 masksWalker: A K95, you can get these online. A lot of people are able to get them. These are good for trying to remove particles. The only problem is they dont get as good of a seal on your face, so theyre not quite as good as a regular N95 would be. But its still a viable option if youre going to be outside.N95 great for actually both COVID and wildfire smoke.For wildfire smoke only: N95 masks with a valveWalker: If youre going to be outdoors by yourself, youre not going to be around other people, youre just going to be maybe doing some yard work, this is the time to wear an N95 with a valve. Itll make it easier for you to breathe. Itll make it so that the air that youre breathing out can exhale beautifully. Just make sure that youre not around other people because that way youre not exposing them to COVID in the event that you do have it.6. How helpful are neck bandanas for COVID and smoke protection?Walker: Unfortunately, the neck bandanas are not terribly helpful. The material theyre made of is very stretchy and thin and so that material makes it very easy for particles to go through. One of the best ways to tell if your mask is too thin is to hold it up and blow out a candle. If you can blow out the candle, youre not protecting people from your droplets.

As Northern California sits under a thick blanket of wildfire smoke for days, many people are left wondering what the air quality means for their health.

It is really bad, said Dr. Vanessa Walker.

As a pulmonary physician with Sutter Health and Pulmonary Medicine Associates, Walker has treated COVID-19 patients throughout the pandemic.

Recently, she has seen an uptick in smoke-related hospital visits. To provide context, she said an AQI greater than 100 is unhealthy for sensitive groups. Right now, the AQI is well over 200.

So this is unhealthy for everybody no matter who you are. And unfortunately, it just seems to be getting worse especially as these wildfires are raging out of control, she said.

Here are six things to know about how smoke impacts your health according to Dr. Walker:

1. What are the negative impacts?

Walker: If you have no lung disease, youre probably just going to notice things like eye irritation, throat irritation, scratchy nose, watery eyes. But if you have any kind of underlying lung disease, COPD, emphysema, asthma, you can cause a serious reaction like an asthma exacerbation or a COPD exacerbation where you have tightening of your airways, significant coughing, shortness of breath and sometimes even life-threatening airway edema.

2. Who are the most vulnerable people?

Walker: The most vulnerable groups are going to be young children, pregnant people as well as people with any kind chronic lung condition or heart condition, and the elderly, mostly because people that are older tend to have those underlying conditions.

3. Is it OK to workout outside (even for just a short amount of time)?

Walker: That is dangerous. You dont know if youre going to be somebody whos out there for 20 minutes and ends up having an asthma exacerbation or a sudden airway problem.

4. What could wildfire smoke mean for contracting COVID-19?

Walker: COVID is setting up an inflammatory bomb in your body. And having underlying inflammation from being exposed to wildfire smoke could actually make it harder for your body to fight because of all the inflammation thats already there.

This is all conjecture because we dont know. This is all early in COVID. This is all new to us. But just understanding basic physiology, it makes perfect sense that if youre already having inflammation, that COVID could come and significantly make it worse.

5. Which masks should you wear to prevent COVID versus wildfire smoke?

For COVID only: Cloth or surgical masks

Walker: If youre going to be indoors, youre going to be around people, youre going to be going to the grocery store, I think wearing a cloth mask is perfectly fine or a regular surgical mask. Completely adequate.

For COVID & wildfire smoke: K95 & N95 masks

Walker: A K95, you can get these online. A lot of people are able to get them. These are good for trying to remove particles. The only problem is they dont get as good of a seal on your face, so theyre not quite as good as a regular N95 would be. But its still a viable option if youre going to be outside.

N95 [masks are] great for actually both COVID and wildfire smoke.

For wildfire smoke only: N95 masks with a valve

Walker: If youre going to be outdoors by yourself, youre not going to be around other people, youre just going to be maybe doing some yard work, this is the time to wear an N95 with a valve. Itll make it easier for you to breathe. Itll make it so that the air that youre breathing out can exhale beautifully. Just make sure that youre not around other people because that way youre not exposing them to COVID in the event that you do have it.

6. How helpful are neck bandanas for COVID and smoke protection?

Walker: Unfortunately, the neck bandanas are not terribly helpful. The material theyre made of is very stretchy and thin and so that material makes it very easy for particles to go through. One of the best ways to tell if your mask is too thin is to hold it up and blow out a candle. If you can blow out the candle, youre not protecting people from your droplets.

Read the rest here:
6 things to know about how wildfire smoke impacts your health - KCRA Sacramento

Adam delivers strong half debut; Callum on strength and conditioning – scottishathletics.org.uk

Saturday 12th September 2020

Adam Craig takes gold at Falkirk in February 2019 at the Lindsays National Xc (photo by Bobby Gavin)

Antrim Results

Adam Craig came up with a very solid half marathon debut as he clocked 63:24 at the Antrim Coast Half Marathon on Saturday morning.

The Inverclyde AC athlete finished in eighth place as Sir Mo Farah headed Marc Scott to win in 60.27.

Craig, who won the Lindsays National XC in 2019, is not far adrift of the top ten in the Scottish all-time rankings with that performance after many months of lockdown.

Inverness Harrier Sean Chalmers was the second best Scot in the Mens race in 13th place in 65:16 and he was closely followed in by James Donald with the Dundee Hawkhill Harrier at 65:27.

Kenny Wilson of Moray Road Runners recorded 67:04 and finished one place below Central AC Irish athlete, Conan McCaughey, who was home in 66:38.

Fiona Brian of Metro Aberdeen delivered the best Scottish performance in the Womens race won by Lily Partridge.

Fiona was placed sixth with a time of 75:33 and her club-mate, Ginie Barrand was 10th with 77:42. Avril Mason of Shettleston was 12th with 78:12 and Claire Bruce of Metro Aberdeen was at 82:19.

+++

Photo by Bobby Gavin

sportscotland interview with Callum

World class athlete Callum Hawkins broke the Scottish record at the London Marathon in April 2019.

He then finished fourth at the IAAF World Championships in Doha to earn pre-selection for the Tokyo 2020 Olympic Games, now due to take place in 2021.

And Callum has been speaking to sportscotland about the importance of strength and conditioning work as he targets even more consistency in his performances.

He credits the support received from thesportscotland institute of sport (SIS), working in collaboration with physical preparation coach Barry Jones as well as the performance physiology and physiotherapy teams, to help him deliver fast times.

Callum, a lifetime member of Kilbarchan AAC, said: Before, I probably dipped in and out of strength and conditioning, but Barry made me fully buy into it and it seems to have worked. I now train twice a week where possible while also getting a lot of massage and physiotherapy.

Going to Doha with the heat it was good to work with SIS physiologist Cian McGinley and Andy Shaw from British Athletics to work out plans and see what I could do in the heat and how I could handle it.

+++

Tags:Adam Craig, Antrim, Callum Hawkins, Fiona Brian

Noticeboard

Noticeboard

Follow this link:
Adam delivers strong half debut; Callum on strength and conditioning - scottishathletics.org.uk

What Makes Memories So Detailed and Enduring? Newly Discovered Mechanism of Learning – SciTechDaily

The tiny red dots are inhibitory nerve cells within the brains hippocampus. The optogenetic tool, shown in green, allows researchers to measure the strength of messages to other nerve cells, using flashes of light. Credit: Matt Udakis

In years to come, personal memories of the COVID-19 pandemic are likely to be etched in our minds with precision and clarity, distinct from other memories of 2020. The process which makes this possible has eluded scientists for many decades, but research led by the University of Bristol has made a breakthrough in understanding how memories can be so distinct and long-lasting without getting muddled up.

The study, published in Nature Communications, describes a newly discovered mechanism of learning in the brain shown to stabilize memories and reduce interference between them. Its findings also provide new insight into how humans form expectations and make accurate predictions about what could happen in future.

Memories are created when the connections between the nerve cells which send and receive signals from the brain are made stronger. This process has long been associated with changes to connections that excite neighboring nerve cells in the hippocampus, a region of the brain crucial for memory formation.

These excitatory connections must be balanced with inhibitory connections, which dampen nerve cell activity, for healthy brain function. The role of changes to inhibitory connection strength had not previously been considered and the researchers found that inhibitory connections between nerve cells, known as neurons, can similarly be strengthened.

Working together with computational neuroscientists at Imperial College London, the researchers showed how this allows the stabilization of memory representations.

Their findings uncover for the first time how two different types of inhibitory connections (from parvalbumin and somatostatin expressing neurons) can also vary and increase their strength, just like excitatory connections. Moreover, computational modeling demonstrated this inhibitory learning enables the hippocampus to stabilize changes to excitatory connection strength, which prevents interfering information from disrupting memories.

First author Dr. Matt Udakis, Research Associate at the School of Physiology, Pharmacology and Neuroscience, said: We were all really excited when we discovered these two types of inhibitory neurons could alter their connections and partake in learning.

It provides an explanation for what we all know to be true; that memories do not disappear as soon as we encounter a new experience. These new findings will help us understand why that is.

The computer modeling gave us important new insight into how inhibitory learning enables memories to be stable over time and not be susceptible to interference. Thats really important as it has previously been unclear how separate memories can remain precise and robust.

The research was funded by the UKRIs Biotechnology and Biological Sciences Research Council, which has awarded the teams further funding to develop this research and test their predictions from these findings by measuring the stability of memory representations.

Senior author Professor Jack Mellor, Professor in Neuroscience at the Centre for Synaptic Plasticity, said: Memories form the basis of our expectations about future events and enable us to make more accurate predictions. What the brain is constantly doing is matching our expectations to reality, finding out where mismatches occur, and using this information to determine what we need to learn.

We believe what we have discovered plays a crucial role in assessing how accurate our predictions are and therefore what is important new information. In the current climate, our ability to manage our expectations and make accurate predictions has never been more important.

This is also a great example of how research at the interface of two different disciplines can deliver exciting science with truly new insights. Memory researchers within Bristol Neuroscience form one of the largest communities of memory-focussed research in the UK spanning a broad range of expertise and approaches. It was a great opportunity to work together and start to answer these big questions, which neuroscientists have been grappling with for decades and have wide-reaching implications.

Reference: Interneuron-specific plasticity at parvalbumin and somatostatin inhibitory synapses onto CA1 pyramidal neurons shapes hippocampal output by Matt Udakis, Victor Pedrosa, Sophie E. L. Chamberlain, Claudia Clopath and Jack R. Mellor, 2 September 2020, Nature Communications.DOI: 10.1038/s41467-020-18074-8

Read the original:
What Makes Memories So Detailed and Enduring? Newly Discovered Mechanism of Learning - SciTechDaily

Jonathan A. Forbes, MD, a Neurosurgeon with the University of Cincinnati Gardner Neuroscience Institute – The Magazine Plus

Get to know Neurosurgeon Dr. Jonathan A. Forbes, who serves patients in Cincinnati, Ohio.

(The Magazine Plus Editorial):- New York City, Sep 11, 2020 (Issuewire.com)Dr. Forbes is a fellowship-trained, board-certified neurosurgeon with expertise and interest in open and minimally-invasive approaches for the treatment of pathology of the cranial base. He treats additional complex neurosurgical pathology of the brain and/or spine at the University of Cincinnati Gardner Neuroscience Institute in Ohio.

There, more than 125 physicians provide treatment to patients and families facing complex neurologic and psychiatric disorders, lead research, and teach the next generation of neuroscience innovators. The experts hold leadership roles in national organizations, developing nationwide standards of care and championing neuroscience research.

More on The Magazine Plus:

In the academic sense, Dr. Forbes serves as an Assistant Professor within the Department of Neurosurgery at Cincinnati College of Medicine, which is one of the leading neurosurgery residency training programs in the country.

As an undergraduate at Grove City College, Dr. Forbes was a recipient of the Trustee Scholarship and was named Sportsman of the Year after his senior season of varsity football. Following the events of 9/11, he enrolled in the Health Professions Scholarship Program with the United States Air Force. In medical school at the University of Pittsburgh School of Medicine, he was a recipient of the David Glasser Honors Award for academic performance. During neurosurgical residency at Vanderbilt University, he received numerous national accoladesincluding the AANS Synthes Craniofacial Award for Research in Neurotrauma as well as the AANS Top Gun Award.

With a commitment to excellence, the doctor attained board certification through the American Board of Neurological Surgery, whose broad aim is to encourage the study, improve the practice, elevate the standards, and advance the science of neurological surgery and thereby serve the cause of public health. His score on the written board examination during his fourth year of residency was recognized in the top 3% nationwide.

After completing his chief year of neurosurgical residency at Vanderbilt in 2013, Dr. Forbes went on to fulfill a four-year commitment with the U.S. Air Force that included a 6-month deployment to Bagram Air Force Base in Afghanistan. Humanitarian care he provided at the Craig Joint Theater Hospital in Bagram has been featured in numerous neurosurgical journalsincluding Journal of Neurosurgery, World Neurosurgery, and Neurosurgical Focusand recognized on a national level by the USAF as part of the Through Airmens Eyes series.

After honorable discharge from the military, he completed a minimally-invasive skull base fellowship at Weill Cornell Medical Center in New York City under the guidance of Dr. Theodore Schwartz prior to joining the UC Department of Neurosurgery.

To date, Dr. Forbes has contributed to over 40 peer-reviewed publications. He has extensive experience with research and endonasal treatment of pituitary tumors and other types of parasellar pathology.

I consider it an incredible privilege to take care of patients with pituitary tumors. I understand the prospect of a neurosurgical intervention can be a very unnerving thing. I have dedicated my life to making sure the surgical intervention we provide is gentle, safe, and effective as stated by Dr. Forbes.

Neurosurgery is the medical specialty concerned with the prevention, diagnosis, surgical treatment, and rehabilitation of disorders which affect any portion of the nervous system including the brain, spinal cord, peripheral nerves, and extra-cranial cerebrovascular system. Neurosurgeons are doctors who diagnose and treat problems with the nervous system, often by performing surgery on the brain or spine. They treat strokes, tumors, cervical and lumbar disc disease, infections, and head or spinal cord injuries.

Learn More about Dr. Jonathan A. Forbes:

Through his findatopdoc profile, https://www.findatopdoc.com/doctor/3192464-Jonathan-Forbes-Surgeon or through UC Health, https://www.uchealth.com/physician/jonathan-forbes/

About FindaTopDoc.com

FindaTopDoc is a digital health information company that helps connect patients with local physicians and specialists who accept your insurance. Our goal is to help guide you on your journey towards optimal health by providing you with the know-how to make informed decisions for you and your family.

Originally posted here:
Jonathan A. Forbes, MD, a Neurosurgeon with the University of Cincinnati Gardner Neuroscience Institute - The Magazine Plus

Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational…

DetailsCategory: DNA RNA and CellsPublished on Saturday, 12 September 2020 14:07Hits: 360

-- Data for Investigational Gene Therapy Treatment NBIb-1817 (VY-AADC) Presented at the MDS Virtual Congress 2020 --

- NBIb-1817 Treatment Showed Sustained Improvement in Motor Function, Including Greater "On" Time without Troublesome Dyskinesia and Reduction in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Scores, and Reduction in the Amount of Medications Up to Three Years in Patients with Parkinson's Disease

- 14 of 15 Patients Treated with NBIb-1817 Continued to Experience an Improvement in Disease Staging after Three Years, as Assessed by the Modified Hoehn & Yahr Scale

- Re-Initiation of Enrollment in Registrational RESTORE-1 Clinical Trial of NBIb-1817 Planned for Later this Year

SAN DIEGO, CA and CAMBRIDGE, MA, USA I September 11, 2020 I Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced data from PD-1101, a Phase Ib open-label, three-year efficacy and safety study, demonstrating that a one-time treatment with investigational gene therapy, NBIb-1817 (VY-AADC), showed sustained improvement in motor function including greater "On" time without troublesome dyskinesia, reduction in Unified Parkinson's Disease Rating Scale (UPDRS) Part III scores, and reduction in the amount of medications in patients with Parkinson's disease.In the PD-1101 study, NBIb-1817 reduced average "Off" time by up to -1.91 hours and improved average "On" time without troublesome dyskinesia by up to +2.23 hours in patients with advanced Parkinson's disease after three years across three cohorts. In addition, 14 out of 15 patients treated with NBIb-1817 continued to show an improvement in disease staging after three years, as assessed by the modified Hoehn & Yahr scale. These new data, along with two-year data from another open-label Phase Ib trial, PD-1102, were presented today at the MDS Virtual Congress 2020, September 1216, 2020 (www.mdscongress.org/Congress/Registration.htm).

In data from the three-year PD-1101 trial, the one-time treatment with NBIb-1817 showed sustained reduction in diary "Off" time by an average of -0.15 to -1.91 hours (baseline 4.28 to 4.93 hours) and improved diary "On" time without troublesome dyskinesia by an average of +0.26 to +2.23 hours (baseline 10.32 to 10.46 hours) across the cohorts as reported by 15 patients with advanced Parkinson's disease. NBIb-1817 also showed sustained improvement in motor function after three years, as measured by UPDRS Part III off medication scores, by -10.2 to -19.0 points (baseline 35.8 to 38.2 points) across the cohorts, per clinician assessment. Requirements for Parkinson's disease medications were also reduced in cohorts 2 and 3 (daily levodopa-equivalent dose reductions, average of -322.0 and -441.2 mg/day, respectively; baseline 1507.0 and 1477.0 mg/day, respectively). Two-year data from the PD-1102 trial for 7 patients showed that NBIb-1817 reduced diary "Off" time by an average of -3.2 hours and increased diary good "On" time by +2.1 hours (baselines 9.3 hours and 6.6 hours, respectively). In this study, NBIb-1817 showed sustained improvement in motor function after two years, with improved UPDRS Part III off medication scores of -12.0 points (baseline 34.4). Requirements for Parkinson's disease medications were also reduced (daily levodopa-equivalent dose reduction, average of -439.5 mg/day; baseline 1500.9 mg/day). Preliminary safety data from both studies suggest that NBIb-1817 was well-tolerated, with no study drug-related serious adverse events (SAEs) reported. The most common adverse events reported were headache, hypoesthesia, and musculoskeletal pain (PD-1101), and upper respiratory tract infection, headache, nausea, and depression (PD-1102).

"It is promising to see that after three years, a single administration of one-time investigational gene therapy treatment NBIb-1817 showed sustained reduction in 'Off' time, as well as improvement in 'On' time without troublesome dyskinesia and other measures of motor function in patients with Parkinson's disease," said Chad Christine, M.D., primary author, a lead investigator of the study and Professor of Neurology at the University of California, San Francisco (UCSF) Weill Institute for Neurosciences. "Parkinson's disease patients' motor function would be expected to worsen over three years, making these results very encouraging. The standard of care for advanced Parkinson's disease has not significantly changed in decades and it is our hope that NBIb-1817 has the potential to become the first gene therapy for Parkinson's disease."

Parkinson's disease is a chronic, progressive and debilitating neurodegenerative disorder that affects approximately one million people in the U.S. and six million people worldwide. It is characterized by a loss of dopamine from neuronal degeneration, with a concomitant loss of the aromatic L-amino acid decarboxylase (AADC) enzyme required to synthesize dopamine in the brain, leading to associated impairment in motor, neuropsychiatric, and autonomic functions.

"We are pleased that the results from these studies show that one-time treatment with investigational NBIb-1817 may help restore the brain's ability to convert levodopa into dopamine," said Eiry Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. "Our hope is that NBIb-1817 will help patients experience less 'Off' time and more 'On' time and improve motor symptom control. We plan to re-initiate enrollment in our registrational RESTORE-1 clinical trial with NBIb-1817 this year and look forward to further evaluating NBIb-1817 in patients with Parkinson's disease."

NBIb-1817 is an investigational recombinant adeno-associated viral serotype 2 vector encoding the gene for human AADC that is designed to help produce the AADC enzyme in brain cells where it can convert levodopa to dopamine.

"We are encouraged by the congruence of long-term data, including clinician- and patient-reported clinical outcomes in our clinical studies," said Omar Khwaja, M.D., Ph.D., Chief Medical Officer and Head of Research and Development at Voyager Therapeutics. "These results are promising and show that the approach has the potential to transform the treatment of Parkinson's disease, and help improve the lives of patients and their families."

Additional information about PD-1101 and PD-1102 will be available on demand for registered participants through October 1, 2020 on the MDS meeting website (www.mdscongress.org/Congress/Registration.htm).

About Parkinson's Disease and NBIb-1817 (VY-AADC) Parkinson's disease is a chronic, progressive and debilitating neurodegenerative disease that affects approximately one million people in the U.S. and six million people worldwide. It is characterized by a loss of dopamine and neuronal degeneration with a concomitant loss of the aromatic L-amino acid decarboxylase (AADC) enzyme required to synthesize dopamine in the brain, leading to associated impairment in motor, neuropsychiatric, and autonomic functions. Dopamine is a chemical "messenger" that is produced in the brain and is involved in the control of movement. It is made when AADC converts the chemical levodopa to dopamine. As Parkinson's disease progresses, there is less AADC enzyme in parts of the brain where levodopa is converted to dopamine.

NBIb-1817 is an investigational recombinant adeno-associated viral (AAV) serotype 2 vector encoding the gene for human AADC that is designed to help produce the AADC enzyme in brain cells where it can convert levodopa to dopamine. NBIb-1817 is administered into the brain using intraoperative monitoring with magnetic resonance imaging (MRI)-facilitated targeted delivery.

About the RESTORE-1 Clinical TrialPaused temporarily in April 2020 due to the COVID-19 pandemic, Neurocrine Biosciences and Voyager Therapeutics plan to re-initiate RESTORE-1, a Phase 2, randomized, placebo-surgery controlled, double-blinded, multi-center clinical trial, to evaluate the safety and efficacy of NBIb-1817 in patients who have been diagnosed with Parkinson's disease for at least four years and have at least three hours of "Off" time during the day as measured by a validated self-reported patient diary.

For more information about the RESTORE-1 clinical trial, including eligibility criteria, please visit clinicaltrials.gov and restore1study.com.

About the RESTORE-2 Clinical TrialPreparations are ongoing for the RESTORE-2 global registrational trial that will include clinical sites within and outside the U.S.

About Neurocrine Biosciences and Voyager Therapeutics Strategic CollaborationIn 2019, Neurocrine Biosciences and Voyager Therapeutics entered into a strategic collaboration focused on the development and commercialization of gene therapy programs, VY-AADC for Parkinson's disease and VY-FXN01 for Friedreich's ataxia, as well as rights to two programs to be determined. This collaboration combines Neurocrine Biosciences' expertise in neuroscience, drug development and commercialization with Voyager's innovative gene therapy programs targeting severe neurological diseases.

About Neurocrine BiosciencesNeurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, with three pivotal and five mid-stage clinical programs in multiple therapeutic areas. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

About Voyager TherapeuticsVoyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager's wholly owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson's disease, Huntington's disease, Friedreich's ataxia, and other severe neurological diseases. For more information on Voyager, please visit the company's website at http://www.voyagertherapeutics.com or follow @VoyagerTx on Twitter and LinkedIn.

SOURCE: Voyager Therapeutics

Read this article:
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational...

Viking genetics and robots working together at Alderston Mains – The Scottish Farmer

Owning a Jersey herd that produces 8100 litres at 5.75%BF and 4.01%P (780kg fat plus protein), can prove problematic knowing where to turn to continue improving performance. But for Andrew Hastie and his family at Alderston Mains near Haddington in East Lothian, the answer has come through a marriage of focussed management, high quality genetics and up-to-date milking technology.

Having experienced success through a combination of the Viking Jersey and robotic milking during a gradual switch over the last three years, the Hasties have decided to follow this process to its logical end. This year, they will add their final two Lely Astronaut A5 robots, bringing their total to six (2 x A4 and 4 x A5), and theyll complete the switch to using genetics exclusively from the Viking countries (Sweden, Finland and Denmark).

With a modest acceptance that the herds production is nearer the top than the bottom, Mr Hastie remarks: Were not really far ahead of the average when you go to Denmark.

And therein lies the overriding reason for the familys choice of genetics, which sees the Vikings gradually take over from all other bloodlines.

The farms foundations were laid in the 1950s when grandfather, David Hastie, started the herd with native UK Jerseys. Since that time, Andrew and his parents, Gordon and Vivian, and brother, David, have fine-tuned both the farm and the herd, to reach the exceptional performance of today.

Over that period, the farm has switched from a mixed enterprise to one thats purely focussed on dairy, with all grass and arable crops across its 400 acres now grown exclusively for the 360-head herd. With a target of increasing the herd to 430 head, the plan is to consolidate numbers at this level.

Weve always enjoyed the Jersey and found her to have robustness and some health benefits over the Holstein, says Mr Hastie. We operate a sort of hybrid system where we want high yields but like the cows to go outside for exercise and grazing even with the robots as we feel its good for their health and keeps our feed costs down in summer.

Close attention has always been paid to the type of genetics that will best meet the farms targets, which began in the earliest days of the herd.

My grandfather was an early adopter of artificial insemination; hed use the best bulls he could get from the USA, New Zealand and Denmark and we continued breeding this mixture for a long time, he said.

Around 15 years ago we dropped the New Zealand bulls, largely because their genetics is driven by milk solids weight-based contracts, which are not quite like our own.

The USA we felt was at the other extreme, and our experience was that the taller, leaner and more angular animals didnt live so long.

We feel the Viking breeding programme has the balance just right, with cows which look long-lasting and producing high quality milk. They are particularly suited to our contract with Grahams Family Dairy, where we need to produce at least 5% fat for the Gold Top range.

In some past summers we had been slightly short of butterfat but find the VikingGenetics bulls are helpful in boosting that.

Around 18 months ago the farm also switched to sexed dairy semen which is now used alongside Aberdeen Angus beef.

Also opting to introduce genomic testing for heifers, Mr Hastie says this is giving an early indication of genetic potential across a range of traits.

When you have a cow on the ground you have a good idea of how she should breed, he says. But with a heifer, all you have is the animals pedigree, so a genomic test adds accuracy for many different traits.

There are also traits on the VikingGenetics bar chart which you dont normally have, he adds. This includes hoof health and saved feed index, which are helping us to breed cows with better feet and more efficiency.

We only started genomic testing recently but plan to test all 200 of our heifer calves born each year, he says. This supplies a linear bar chart, just like youd have for a bull, and you can see straight away what you need to improve.

It also ranks the heifers on the Nordic Total Merit [NTM] index, which is not unlike the UKs PLI [Profitable Lifetime Index].

Also using VikMate, the VikingGenetics mating program, Mr Hastie is able to set his own targets and receive a best-choice mating for each animal in the herd.

He says: If I want to focus on a particular trait, I can change that myself when running the program. This could be for hoof health, stature, milk quality or any other trait.

In fact, were already seeing big improvements in feet and legs through corrective breeding and starting to see changes in other areas.

This includes reducing udder depth and strengthening udder support we think theyll remain higher for longer and making other changes to help robotic milking.

This has involved a change of mindset and were now looking to widen rear teat placement as well as lengthen teats something we didnt do in the past.

We have also moved away from selection for production, now keeping our focus on health and functional traits. We have found that the milk is there, even without looking for it, which allows us to focus improvement on other areas.

Also aiming to improve the herds management and efficiency, the next robots to be installed will help in this endeavour.

He says: Our sixth robot will be a grazing robot, which will be used exclusively by our late lactation cows. Theyll be in strawed yards in winter and graze in summer, only receiving concentrates while at grass, when theyre having no total mixed ration.

Im confident well maintain their yields and should manage body condition score better. I think it will save 1-2 per head each day in feed costs for the last 30-40 days of lactation.

Asked how the Viking-bred cattle have impacted profitability, he believes its too early to say with any precision.

In a few years, when nearly all the herd is Danish, Ill be able to tell you but all I can say now is that we are very pleased.

FARM facts

360 milking Jerseys rising to 430 in year-round calving system

Production at 8100 litres at 5.75%BF and 4.01%P (780kg fat plus ptn)

All breeding switched to VikingGenetics for longevity and milk quality

Four A4/A5 Lely robots, increasing to six, including one grazing robot

Sexed semen produces 200 Jersey heifers/year for replacements and sale

Genomic testing introduced for all Jersey heifer calves this year

TMR fed to all milking groups except late lactation, plus concentrates to yield

Follow this link:
Viking genetics and robots working together at Alderston Mains - The Scottish Farmer